Logo image of MLYS

MINERALYS THERAPEUTICS INC (MLYS) Stock Fundamental Analysis

NASDAQ:MLYS - Nasdaq - US6031701013 - Common Stock - Currency: USD

10.52  -0.02 (-0.19%)

After market: 11.6 +1.08 (+10.27%)

Fundamental Rating

3

Taking everything into account, MLYS scores 3 out of 10 in our fundamental rating. MLYS was compared to 572 industry peers in the Biotechnology industry. MLYS has a great financial health rating, but its profitability evaluates not so good. MLYS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MLYS had negative earnings in the past year.
MLYS had a negative operating cash flow in the past year.
MLYS had negative earnings in each of the past 5 years.
In the past 5 years MLYS always reported negative operating cash flow.
MLYS Yearly Net Income VS EBIT VS OCF VS FCFMLYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

MLYS has a Return On Assets of -86.36%. This is in the lower half of the industry: MLYS underperforms 70.16% of its industry peers.
MLYS has a Return On Equity (-92.97%) which is in line with its industry peers.
Industry RankSector Rank
ROA -86.36%
ROE -92.97%
ROIC N/A
ROA(3y)-46.99%
ROA(5y)-109.19%
ROE(3y)-50.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MLYS Yearly ROA, ROE, ROICMLYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MLYS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MLYS Yearly Profit, Operating, Gross MarginsMLYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

MLYS has more shares outstanding than it did 1 year ago.
MLYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MLYS Yearly Shares OutstandingMLYS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
MLYS Yearly Total Debt VS Total AssetsMLYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

MLYS has an Altman-Z score of 17.45. This indicates that MLYS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 17.45, MLYS belongs to the top of the industry, outperforming 92.84% of the companies in the same industry.
There is no outstanding debt for MLYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.45
ROIC/WACCN/A
WACCN/A
MLYS Yearly LT Debt VS Equity VS FCFMLYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 14.02 indicates that MLYS has no problem at all paying its short term obligations.
With an excellent Current ratio value of 14.02, MLYS belongs to the best of the industry, outperforming 88.66% of the companies in the same industry.
MLYS has a Quick Ratio of 14.02. This indicates that MLYS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 14.02, MLYS belongs to the top of the industry, outperforming 88.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.02
Quick Ratio 14.02
MLYS Yearly Current Assets VS Current LiabilitesMLYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MLYS have decreased strongly by -82.00% in the last year.
EPS 1Y (TTM)-82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MLYS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.46% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.73%
EPS Next 2Y-2.46%
EPS Next 3Y-2.97%
EPS Next 5Y18.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MLYS Yearly Revenue VS EstimatesMLYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
MLYS Yearly EPS VS EstimatesMLYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MLYS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLYS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLYS Price Earnings VS Forward Price EarningsMLYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLYS Per share dataMLYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

MLYS's earnings are expected to decrease with -2.97% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.46%
EPS Next 3Y-2.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MLYS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MINERALYS THERAPEUTICS INC

NASDAQ:MLYS (3/7/2025, 8:00:01 PM)

After market: 11.6 +1.08 (+10.27%)

10.52

-0.02 (-0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12 2025-02-12/bmo
Earnings (Next)05-07 2025-05-07
Inst Owners94.14%
Inst Owner Change4.79%
Ins Owners2.53%
Ins Owner Change0.27%
Market Cap524.32M
Analysts85.71
Price Target32.64 (210.27%)
Short Float %4.15%
Short Ratio5.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.99%
Min EPS beat(2)-32.79%
Max EPS beat(2)10.8%
EPS beat(4)1
Avg EPS beat(4)-10.24%
Min EPS beat(4)-32.79%
Max EPS beat(4)10.8%
EPS beat(8)5
Avg EPS beat(8)14.33%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.75%
PT rev (3m)-1.75%
EPS NQ rev (1m)5.48%
EPS NQ rev (3m)5.48%
EPS NY rev (1m)-2.73%
EPS NY rev (3m)-1.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.74
P/tB 2.74
EV/EBITDA N/A
EPS(TTM)-3.64
EYN/A
EPS(NY)-4.03
Fwd EYN/A
FCF(TTM)-3.34
FCFYN/A
OCF(TTM)-3.34
OCFYN/A
SpS0
BVpS3.84
TBVpS3.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -86.36%
ROE -92.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.99%
ROA(5y)-109.19%
ROE(3y)-50.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 223.26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.02
Quick Ratio 14.02
Altman-Z 17.45
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60.66%
EPS Next Y-10.73%
EPS Next 2Y-2.46%
EPS Next 3Y-2.97%
EPS Next 5Y18.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-127.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.05%
EBIT Next 3Y-12.22%
EBIT Next 5Y24.38%
FCF growth 1Y-105.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.89%
OCF growth 3YN/A
OCF growth 5YN/A